title: Low dose of cyproterone acetate and testosterone enanthate for contraception in men.
abstract: After a control phase, 10 normal men received cyproterone acetate (CPA) at a dose of 25 mg/day (CPA-25; n=5) or 12.5 mg/day (CPA-12.5; n=5) plus testosterone enanthate (TE) 100 mg/week, for 16 weeks. Throughout the study sperm counts were performed every 2 weeks, and luteinizing hormone (LH), follicle stimulating hormone (FSH), testosterone, biochemical and haematological tests were performed every 4 weeks. All five men in group CPA-25 and three men in group CPA-12.5 achieved azoospermia. One man in group CPA-25 was azoospermic by week 12 of hormone administration, but had a sperm count of 0.1 x 10(6)/ml at week 16. Time to azoospermia was 9.0+/-1.3 and 8.7+/-0.7 weeks in groups CPA-25 and CPA-12.5 respectively. Gonadotrophins were decreased by week 4 of hormone administration, remained around the minimum detectability of the assay for the duration of hormone administration and returned to baseline after stopping hormone administration. Testosterone values did not change. No change in any biochemical parameters was found. Haematological parameters were decreased at week 16 of hormone administration and returned to baseline after stopping hormone administration. In conclusion, these results suggest that an hormonal regimen consisting of testosterone plus a progestin with anti-androgenic properties holds promise as an effective, safe and reversible male contraceptive.
authors.affiliation: Department of Obstetrics and Gynecology and Core Lab, S.Orsola Hospital, University of Bologna, Italy.
authors.forename: M C
authors.initials: MC
authors.lastname: Meriggiola
authors.forename: W J
authors.initials: WJ
authors.lastname: Bremner
authors.forename: A
authors.initials: A
authors.lastname: Costantino
authors.forename: G
authors.initials: G
authors.lastname: Di Cintio
authors.forename: C
authors.initials: C
authors.lastname: Flamigni
mesh_terms: D000328:Adult; D003272:Contraceptive Agents, Male / Q000008:administration & dosage* / Q000009:adverse effects; D017373:Cyproterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D005640:Follicle Stimulating Hormone / Q000097:blood; D006400:Hematocrit; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008055:Lipids / Q000097:blood; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009845:Oligospermia / Q000139:chemically induced; D012449:Safety; D013076:Sperm Count; D013091:Spermatogenesis / Q000187:drug effects; D013737:Testis / Q000187:drug effects / Q000473:pathology; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood; D013997:Time Factors
chemical_list: D003272:Contraceptive Agents, Male; D006454:Hemoglobins; D008055:Lipids; D013739:Testosterone; D017373:Cyproterone Acetate; C004648:testosterone enanthate; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone